Engflag

CELESTAN-V

Quick links to important sections

CELESTAN-V

There is no image.

Method of action: Antiallergic, Antiexudative, Anti-Inflammatory, Antiproliferative, Antipruritic, Corticosteroids For Systemic Use, Corticosteroids, Dermatological Preparations, Decongestant, Glucocorticoid, Immunosuppressive

Treatment option: Allergic Reactions, Allergic Conjunctivitis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Plaque Psoriasis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CELESTAN-V

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate (often combined with another agent)
Form Cream, Ointment, Lotion, Gel (Topical)
Pharmacological class Glucocorticoid (Corticosteroid Hormone)
General purpose Relief from inflammatory skin conditions
Origin Synthetic (Fluorinated Steroid)

What Type of Medicine is CELESTAN-V?

CELESTAN-V is a trade name for a topical corticosteroid preparation that commonly contains the active ingredient Betamethasone Dipropionate, often found in combination with other agents such as gentamicin (a topical antibiotic) in some international markets. This substance is classified within the major pharmacological group of glucocorticoid hormones and is designated as prescription-only. The active component is a specialized, synthetic adrenocorticosteroid, which is a fluorinated derivative designed for maximum anti-inflammatory action when applied topically.

Understanding its Form and Differentiation

The medication is intended exclusively for the Topical route of administration, distinguishing it from systemic corticosteroids. It is supplied in various pharmaceutical preparations, including cream, ointment, lotion, and gel forms, each utilizing a specific base or vehicle. The specific chemical structure, the dipropionate ester, contributes to its high potency compared to simpler betamethasone forms. The formulation and base used define its final potency classification, which can range from High Potency to Super High Potency.

What is its General Purpose?

The general purpose of this medicine is to provide effective relief from the inflammatory and pruritic manifestations that define a variety of corticosteroid-responsive dermatoses. As a powerful anti-inflammatory agent, the active ingredient works locally to suppress the cellular mechanisms that cause chronic inflammation, redness, and swelling. This function is clinically recognized for quickly relieving the intense, uncomfortable itching associated with various inflammatory skin conditions.

Regulatory References

  1. FDA DailyMed Labeling: Betamethasone Dipropionate

What side effects are possible with CELESTAN-V?

Possible Side Effects and Safety Information

The safety profile for CELESTAN-V, which contains the high-potency topical corticosteroid Betamethasone Dipropionate, is defined by both local skin reactions and the potential for systemic effects through absorption. Adverse reactions are classified according to frequency and body system in regulatory documentation.

Local Adverse Reactions and Frequency

The majority of documented effects are local and occur at the site of application. These are generally classified in regulatory labels as Common or Infrequent and include local reactions such as a burning sensation, itching (pruritus), irritation, and dryness.

Less common local effects and serious skin disorders include folliculitis, acneiform eruptions, perioral dermatitis, and more severe issues associated with long-term use, such as skin atrophy (thinning), striae (stretch marks), and telangiectasia (visible superficial blood vessels).

Systemic Risk and Serious Adverse Reactions

High-level regulatory sources document the potential for significant systemic absorption, which can lead to serious adverse reactions classified as Rare or Infrequent. These events include Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression, which can manifest as features of Cushing's syndrome. Ophthalmic risks, such as Glaucoma and Cataracts, have also been reported post-marketing (frequency often classified as Not Known).

Safety Considerations by Duration and Population

  • Duration-Related Patterns: The risk of both local effects, such as skin atrophy, and systemic effects, such as HPA axis suppression, is increased with prolonged or long-term use, application to large body areas, and the use of occlusive dressings. Cessation after long-term use carries a risk of Topical Steroid Withdrawal Syndrome.
  • Pediatric Patients: Children are documented to have greater susceptibility to HPA axis suppression due to a higher skin surface area to body mass ratio. Systemic effects in this population can potentially manifest as linear growth retardation. Pregnancy and Lactation require specific consideration, as the compound can pass into breast milk.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from topical Betamethasone Dipropionate (CELESTAN-V) is primarily a risk associated with systemic absorption following prolonged use, application over a large surface area, or use under occlusion, rather than acute ingestion. The official regulatory profile is focused on the resulting systemic effects of overexposure.

Documented Manifestations and Severe Outcomes

Excessive systemic absorption can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression and manifestations resembling Cushing’s syndrome. Documented physiological signs of overexposure include hyperglycemia and glucosuria. Severe outcomes include the potential for life-threatening glucocorticosteroid insufficiency upon withdrawal and documented risks of cataracts and glaucoma.

Required Emergency Actions

Urgent medical attention must be sought immediately if visual symptoms occur, as this may signal serious ophthalmic risk. If HPA suppression is confirmed by required monitoring tests (such as the ACTH stimulation test), official regulatory documents state the management involves attempting to withdraw the drug or substitute with a less potent steroid.

Population-Specific Risk

Pediatric patients are at a heightened risk of systemic toxicity due to a greater skin surface area to body mass ratio. Systemic effects in children include linear growth retardation and delayed weight gain, which require careful monitoring as mandated by official labeling.

Therapeutic Uses of CELESTAN-V

What CELESTAN-V Treats: Main Uses and Benefits

CELESTAN-V is generally relevant in clinical settings that involve acute or unstable symptom patterns arising from chronic conditions. It is considered relevant for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This covers conditions such as severe psoriasis, various forms of eczema (atopic dermatitis, contact dermatitis), and chronic skin disorders like lichen simplex chronicus.

The medication is commonly applied when supportive symptom management is appropriate because symptoms have become more disruptive during flare-ups. It helps address symptom clusters that may become intense, focusing on relieving intense itching, pronounced redness, and localized swelling. This action supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

--- Quick Fact: Role in Symptomatic Management

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

The official regulatory profile for CELESTAN-V (Betamethasone Dipropionate topical) defines specific rules regarding who can and cannot use the medicine. The medicine is generally approved for use in patients 13 years of age and older.

Populations Not Eligible

Use is contraindicated for patients with a known hypersensitivity to the active ingredient, other corticosteroids, or any non-active ingredients in the formulation. The medicine must also not be used if the patient has certain local skin conditions, such as rosacea or perioral dermatitis.

Age and Conditional Use

The safety and effectiveness have not been established for use in pediatric patients 12 years of age and younger, and this age group is not recommended for treatment. Use is restricted for populations with increased risk of systemic absorption, including those with liver failure or pre-existing conditions like diabetes or glaucoma.

Specific Restrictions

For women who are pregnant, use is conditional (e.g., Category C) and permitted only if the potential benefit justifies the potential risk to the fetus. The medicine must not be applied to specific body areas, including the face, groin, or axillae (underarms), or to any skin that shows signs of atrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Betamethasone Dipropionate topical, the active substance in CELESTAN-V, defines interaction risks based on the potential for systemic absorption rather than direct metabolic drug-drug interactions. The interaction structure is dominated by pharmacodynamic effects.

Interaction Category Documented Information from Regulatory Sources
Pharmacodynamic Reinforcement Co-administration with other corticosteroid-containing products (systemic or topical) leads to additive glucocorticoid effects. This constitutes a pharmacodynamic reinforcement of the total corticosteroid load.
Exposure-Altering Risk This additive effect raises the risk of increased systemic exposure to Betamethasone. The documented outcome of this exposure increase is the risk of reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and signs of Cushing's syndrome as stated in regulatory materials.
Contraindicated Combinations No specific medicinal product or substance combination is formally listed as a drug-drug contraindication in official labels.
Metabolic Interactions Regulatory documents do not detail specific interactions mediated by CYP enzymes, drug transporters, food, alcohol, or herbal products for this topical formulation.

Population-Specific Interaction Considerations

Official labeling highlights specific patient populations with heightened sensitivity to the systemic effects resulting from this exposure increase. Pediatric patients are identified as having a greater risk of systemic toxicity and resultant interaction outcomes due to a larger skin surface area to body mass ratio. Patients with liver failure are also noted to be predisposed to HPA axis suppression because of their altered capacity for systemic drug clearance.

The interaction profile confirms that the primary constraint is the total corticosteroid burden on the body, which is managed through restrictions on concurrent use of other steroid medicines.

Mechanism of Action

How CELESTAN-V Works

Modulating Receptor-Mediated Signaling Pathways

CELESTAN-V acts within domains involving receptor-mediated signaling by engaging mechanisms that regulate dysregulated processes driven by specific signaling patterns. The compound functions as an agonist at specific cellular receptors, altering their conformational state. This interaction modifies early molecular steps within the intracellular pathway, contributing to the modulation of heightened physiological pathway activity.

Influencing Inflammatory and Immune System Mediators

The drug affects systems where specific transmitters or mediators dominate, engaging in mechanisms that result in the suppression of excessive mediator release. It initiates or suppresses signaling sequences that lead to downstream effects in inflammatory cascades, thereby influencing pathway feedback mechanisms and transcription factor activity.

Regulating Cellular Feedback and Systemic Adjustment

CELESTAN-V is relevant in systems where targeted pathway adjustment is required. It supports the regulation of processes driven by distinct signaling patterns by engaging mechanisms that influence feedback regulation within pathways. This action results in downstream changes in cellular and physiological processes, contributing to a controlled systemic modulation of activity.

Dosage and Administration Information

Administration Guidelines for CELESTAN-V

CELESTAN-V, a topical corticosteroid (Betamethasone Dipropionate), is used in accordance with established medical protocols. The medication is for topical use only and must not be used orally, ophthalmically (in the eyes), or intravaginally.

Feature Instruction
Route of Administration Topical use (on the skin surface only)
Standard Dosing Schedule Apply a thin film to the affected areas once or twice daily.
Duration Limit (Augmented Form) Therapy is typically limited to no more than 2 consecutive weeks (for high-potency/augmented formulations).
Maximum Use Total dose should not exceed 50 grams per week.

If no improvement is observed after two weeks of use, a reassessment of the condition and treatment plan is appropriate.

Procedural and Age Constraints

The standard protocol requires specific application constraints. The medication should not be used with occlusive dressings (airtight bandages or wraps) unless specifically instructed by a medical professional. Application must be avoided on the face, groin, and underarm areas (axillae). The cream and ointment forms are indicated for use in patients 13 years of age and older, with use in younger children generally not recommended.

Recent Clinical Evidence

Research Evidence / Overview of studies for CELESTAN-V

The primary research for CELESTAN-V (Betamethasone Dipropionate) focuses on short-term Randomized Controlled Trials (RCTs) exploring conditions characterized by fluctuating or episodic manifestations, such as plaque psoriasis and certain forms of eczema. These studies were applied in research contexts to explore patterns observed when the medicine was compared to an inactive base, known as the vehicle.

In these trials, research examined outcomes linked to inflammatory or irritative states. Studies monitored clinical status by observing how symptoms evolved using standardized scales, such as the Physician's Global Assessment (PGA) and the Psoriasis Area and Severity Index (PASI). Findings describe group patterns, not personal outcomes, related to how the skin's appearance and the patient's discomfort evolved during the study period.

Pivotal studies primarily focused on research exploring short-term symptom changes, generally observing responses over defined time intervals of 2 to 4 weeks. Because follow-up durations were limited, long-term effects are not fully established, and certainty remains low concerning the durability of any observed patterns or the frequency of relapse.

The research primarily included adults with moderate to severe conditions. Adolescents (aged 12 and older) was studied for systemic effects to understand systemic exposure parameters. However, data for certain groups remain insufficient, and the results apply only to the populations studied, meaning the evidence base has limited information for long-term outcomes or complex patient subgroups.

Key Studies & References

  1. Label: BETAMETHASONE DIPROPIONATE cream (Augmented) - DailyMed (FDA-mandated information, including clinical trial summaries)
  2. Safety and Efficacy of Taclonex (Daivobet) Ointment in Adolescent Patients (aged 12 to 17 years) with Psoriasis Vulgaris (MCB 0501 INT) - Paediatric Public Assessment Report (EMA-related document)

Frequently Asked Questions (FAQ)

Common questions about CELESTAN-V (FAQ)

Q: Will applying betamethasone dipropionate cream make me feel dizzy or tired (fatigue)?

Official documents note that when topical corticosteroids are absorbed by the body, they can potentially lead to systemic effects. These systemic effects, which involve the adrenal glands, are related to conditions where unusual tiredness or fatigue can occur. Other potential systemic issues described include visual changes, such as blurred vision, which have been noted in post-marketing reports. This information is based on regulatory source findings about systemic absorption risk.

Q: Can betamethasone dipropionate cream cause high blood pressure or weight changes?

According to official product information, the systemic absorption of CELESTAN-V (betamethasone dipropionate) has the potential to produce effects related to endocrine system changes. These effects include manifestations that resemble Cushing’s syndrome, as well as high blood sugar (hyperglycemia). Since this systemic exposure can lead to manifestations resembling Cushing’s syndrome, the potential for related symptoms, such as weight change or elevated blood pressure, is noted in the regulatory descriptions.

Q: Is there a generic version of betamethasone dipropionate cream available?

Yes, regulatory databases confirm that the active ingredient in CELESTAN-V, which is betamethasone dipropionate cream (often the augmented 0.05% formulation), is available in generic versions. These generic versions have been approved by the FDA and are listed in official regulatory documentation alongside the branded product.

How should CELESTAN-V be stored and disposed of?

Storage and Disposal Information

Official regulatory guidelines for CELESTAN-V (Betamethasone Dipropionate topical) mandate specific conditions to maintain product stability and ensure safety.

Storage Requirement Condition
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect the product from freezing, excessive heat, moisture, and direct light.
Handling Keep the container tightly closed and store in a safe location.
Child Safety Keep out of the sight and reach of children at all times.

Expired or unused CELESTAN-V must be disposed of properly. Do not flush the medicine down the toilet or pour it into a drain. Disposal must follow state and local regulations for pharmaceutical waste, adhering to environmental protection rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of CELESTAN-V found in:

A-Z Index: